The contribution of community pharmacists during the COVID-19 pandemic

Disease Management Services

21

Disease Management Services

Directly observed treatment/Supervised Consumption of Medicines

First time dispensing intervention (e.g. New Medicines Service)

Administering injectable medicines (e.g. antibiotics)

Instruction on use of therapeutic, self-monitoring device or medical aid (e.g. stoma appliance, inhaler, insulin device)

Teleconsultations by pharmacists

Therapeutic Adherence Support

Chronic disease management (e.g. hypertension, hyperlipidemia, diabetes, asthma, COPD, NOAC)

Data Collection on the effectivness of new medicines

4

1

3

2

3

2

1

5

2

9

3

6

7

7

5

3

1

2

3

1

Remunerated by Government/Health Payer

Provided in most pharmacies under contract, agreement or regulation

Provided in some pharmacies as pilot

Number of European countries

PGEU Annual Report 2021

Community pharmacists exemplar role as primary care providers in the COVID-19 pandemic

X

PGEU Members 2021

PGEU Executive Committee 2021

PGEU Secretariat

A look forward

2021 at a glance

Foreword Alain Delgutte,

PGEU President 2021

The contribution of community

pharmacists during the COVID-19